Litcius/Paper detail

Randomized, Placebo Controlled Trial of Experimental Hookworm Infection for Improving Gluten Tolerance in Celiac Disease

John Croese, Gregory Miller, Louise Marquart, Stacey Llewellyn, Rohit Gupta, Luke Becker, Andrew D. Clouston, Christine Welch, Julia Sidorenko, Leanne Wallace, Peter M. Visscher, Matthew Remedios, James McCarthy, Peter O’Rourke, Graham Radford‐Smith, Alex Loukas, Mark Norrie, John Masson, Richard B. Gearry, Tony Rahman, Paul Giacomin

2020Clinical and Translational Gastroenterology50 citationsDOIOpen Access PDF

Abstract

INTRODUCTION: Celiac disease is an autoimmune disorder where intestinal immunopathology arises after gluten consumption. Previous studies suggested that hookworm infection restores gluten tolerance; however, these studies were small (n = 12) and not placebo controlled. METHODS: We undertook a randomized, placebo-controlled trial of hookworm infection in 54 people with celiac disease. The 94-week study involved treatment with either 20 or 40 Necator americanus third-stage larvae (L3-20 or L3-40) or placebo, followed by escalating gluten consumption (50 mg/d for 12 weeks, 1 g intermittent twice weekly for 12 weeks, 2 g/d sustained for 6 weeks, liberal diet for 1 year). RESULTS: Successful study completion rates at week 42 (primary outcome) were similar in each group (placebo: 57%, L3-20: 37%, and L3-40: 44%; P = 0.61), however gluten-related adverse events were significantly reduced in hookworm-treated participants: Median (range) adverse events/participant were as follows: placebo, 4 (1-9); L3-20, 1 (0-9); and L3-40, 0 (0-3) (P = 0.019). Duodenal villous height:crypt depth deteriorated similarly compared with their enrolment values in each group (mean change [95% confidence interval]: placebo, -0.6 [-1.3 to 0.2]; L3-20, -0.5 [-0.8 to 0.2]; and L3-40, -1.1 [-1.8 to 0.4]; P = 0.12). A retrospective analysis revealed that 9 of the 40 L3-treated participants failed to establish hookworm infections. Although week 42 completion rates were similar in hookworm-positive vs hookworm-negative participants (48% vs 44%, P = 0.43), quality of life symptom scores were lower in hookworm-positive participants after intermittent gluten challenge (mean [95% confidence interval]: 38.9 [33.9-44] vs 45.9 [39.2-52.6]). DISCUSSION: Hookworm infection does not restore tolerance to sustained moderate consumption of gluten (2 g/d) but was associated with improved symptom scores after intermittent consumption of lower, intermittent gluten doses.

Topics & Concepts

PlaceboMedicineNecator americanusGlutenGastroenterologyHookworm infectionInternal medicineAdverse effectConfidence intervalHookworm InfectionsRandomized controlled trialImmunologyHelminthiasisHelminthsPathologyAlternative medicineAscaris lumbricoidesCeliac Disease Research and ManagementParasites and Host InteractionsDigestive system and related health